MADCAM1 and type 1 diabetes mellitus: Monoclonal antibodies against MADCAM1 and  are showing clinical benefits in inflammatory bowel disease [Sheridan, 2014], and hence based on our genetic results presented here, investigation of the effects of these drugs in T1D is worth considering.